According to the World Health Organization, the average coverage of basic vaccines in GAVI's target nations is approximately 80% compared to an average immunisation rate of 67% in 2000.
Despite tremendous gains in vaccine access, however, children often do not receive appropriate antibiotic treatment for pneumonia cases that do occur. These findings are underscored in a report issued today by IVAC, which shows that while progress is being made with vaccination in the 15 countries with the most child pneumonia deaths, the latest data show that all of these countries have sub-optimal levels of protection and treatment interventions, including exclusive breastfeeding, access to care facilities and treatment with antibiotics.
"Vaccines and antibiotic treatments are like two safety nets that work together vaccines provide a first line of defense, while antibiotics ensure that children who get through the first net don't die," said Orin Levine, professor and executive director of IVAC. "We must sustain the tremendous progress achieved this year in vaccines and expand access to antibiotic treatment to fully tackle this disease."
In a new study to be published today in International Health, the analyses show that both the 10-valent and 13-valent pneumococcal vaccines being rolled out now in GAVI-supported countries are a "best buy" and their value for money is highest in the countries at greatest risk findings that holds up in spite of challenges with data collection in several of the countries covered in the analysis.
"We know the vaccines can save hundreds of thousands of lives every year throughout the developing world," said Anushua Sinha, a senior author on the study and associate professor in the Department of Preventive Medicine and Community Health at the University of Medicine & Dentistry of New Jer
|Contact: Coimbra Sirica|